tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Entero Therapeutics Granted Nasdaq Compliance Extension

Story Highlights
Entero Therapeutics Granted Nasdaq Compliance Extension

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Entero Therapeutics ( (ENTO) ) has issued an update.

On June 25, 2025, Entero Therapeutics, Inc. received an extension from Nasdaq until October 8, 2025, to comply with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company had previously been notified on April 11, 2025, of its non-compliance due to a stockholders’ equity of negative $3,876,738, which was below the required $2.5 million. Failure to meet these requirements could result in delisting, although the company has the option to appeal any delisting decision.

More about Entero Therapeutics

Average Trading Volume: 1,625,643

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.81M

Find detailed analytics on ENTO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1